ArriVent BioPharma (AVBP) vs Verastem (VSTM)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Verastem (VSTM) has outperformed ArriVent BioPharma (AVBP) over the past year, losing 9.3% versus a loss of 19.7%. ArriVent BioPharma is the larger company by market cap ($823.9 million vs $734.5 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AVBP | VSTM |
|---|---|---|
| Share price | $16.71 | $8.11 |
| Market cap | $823.93M | $734.47M |
| 1-day change | -1.07% | -1.88% |
| YTD return | -16.95% | +5.05% |
| 1-year return | -19.74% | -9.28% |
| 5-year return | — | -75.51% |
| EPS (TTM) | $-3.62 | $-2.45 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $35.83 | $10.82 |
| 52-week low | $11.36 | $3.43 |
| Distance from 52-week high | -53.36% | -25.05% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +82.53% | +84.96% |
| Average volume | 908.55K | 2.25M |
| Shares outstanding | 49.31M | 90.56M |
| Employees | 77 | 102 |
| Sector | Health Care | Healthcare |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- VSTM has outperformed AVBP by 10.5 percentage points over the past year.
- The two companies sit in different sectors: ArriVent BioPharma in Health Care and Verastem in Healthcare.
About ArriVent BioPharma
AVBP stock →ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. The company's lead development candidate is firmonertinib, a tyrosine kinase inhibitor that is being evaluated in multiple clinical trials across a range of epidermal growth factor receptor mutations (EGFRm) in non-small cell lung cancer (NSCLC), including a Phase 3 clinical trial for treatment of patients with advanced or metastatic EGFRm NSCLC with exon 20 insertion mutations, as well as Phase 1b clinical trials to treat NSCLC patients with activating EGFRm, including P-loop and-alpha-c-helix compressing (PACC) mutations, and classical EGFRm NSCLC patients.
Health Care · Biotechnology: Pharmaceutical Preparations · 77 employees
About Verastem
VSTM stock →Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, which is an orally administered, small molecule dual RAF/MEK inhibitor developed to block MEK kinase activity and the compensatory reactivation of MEK by upstream RAF, thereby targeting the RAS/MAPK signaling pathway that is commonly activated in various cancers; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors.
Healthcare · Biotechnology · 102 employees
AVBP vs VSTM FAQ
Which is bigger, ArriVent BioPharma or Verastem?
ArriVent BioPharma (AVBP) is larger, with a market capitalization of $823.93M compared with $734.47M for Verastem (VSTM).
Which stock has performed better over the past year, AVBP or VSTM?
VSTM returned -9.28% over the past 12 months, compared with -19.74% for AVBP (price return, excluding dividends). Past performance does not predict future results.
Are ArriVent BioPharma and Verastem in the same industry?
No. ArriVent BioPharma is in the Health Care sector, while Verastem is in Healthcare.